newsfilter
← Latest News
Business Wire·

AlloVir Appoints Derek Adams, Ph.D., to Board of Directors

AlloVir (NASDAQ:ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced the appointment of Derek Adams, Ph.D., to its Board of Directors, effective March 1, 2023. Dr. Adams brings more than